WHO

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Mosquito
#Malaria #Novartis #WHO

WHO prequalifies world’s first antimalarial drug for newborns 

The world’s first and only malaria drug for newborns has been cleared globally, marking a crucial step towards addressing a long-standing gap in malaria care.  Coartem (artemether-lumefantrine) Baby, developed by Medicines for Malaria Venture (MMV) and Novartis, has been prequalified by the World Health Organization (WHO) as the first and only antimalarial… Read More

#News #Regulatory

Antibiotics
#ABPI #Antibiotics #Antimicrobial resistance (AMR) #Antivirals #United Nations #WHO

Access to medicines vital in tackling AMR, world leaders agree

Global leaders have approved a plan to reduce the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance (AMR) annually by 10% by 2030. The political declaration was agreed at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). Read More

#News #Trending News

Mosquito against yellow background
#Immunology / Virology & Vaccines #Malaria #Novavax #Serum Institute of India #University of Oxford #WHO

WHO recommends new cost-effective malaria vaccine

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine demonstrates high efficacy with… Read More

#News #Regulatory #Trending News

Antibiotics
#Antibiotic resistance #Antimicrobial resistance (AMR) #WHO

Research into antibiotic-resistant pathogens sees increase since 2017

Research into antibiotic-resistant priority pathogens has boomed in the five years since the World Health Organisation (WHO) released a list of 12 families of bacteria that desperately need new antibiotics.  Data from Elseveir’s Scopus database show that since 2017, 227,808 papers have been published on the 12… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Infectious diseases #WHO

WHO updates Covid-19 strategy to reach unvaccinated  

The World Health Organisation (WHO) has released an update to its ongoing global Covid-19 strategy in order to reach individuals yet to be vaccinated.   The update to WHO’s Global Covid-19 Vaccination Strategy1, was made in response to the spread of Omicron subvariants, advances in vaccine evidence, and… Read More

#News

#Antibiotics #Antimicrobial resistance (AMR) #Vaccines #WHO

Urgency a must for global fight against AMR, report says  

Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO).  WHO has released the first-ever report1 looking at the pipeline of vaccines currently in… Read More

#News #Trending News

#Antivirals #Covid-19 #WHO

WHO recommends Pfzier’s antiviral combo for Covid-19 patients  

The World Health Organisation (WHO) has strongly recommended a combination of antiviral drugs for patients at a high risk of hospital admission due to Covid-19.   The WHO is recommending Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) for patients with non-severe covid-19 who are… Read More

#News